The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...

We recently compiled a list of the Best Future Stocks For The Long-Term. In this article, we will look at where Pfizer Inc.

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Shares of Pfizer Inc. PFE dropped 0.81% to $29.42 Friday, on what proved to be an all-around mixed trading session for the ...

In the closing of the recent trading day, Pfizer (PFE) stood at $29.42, denoting a -0.83% change from the preceding trading day.

New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.

Pending authorization of the Omicron KP.2-adapted vaccine by the EC, both the Omicron KP.2-adapted vaccine and the Omicron JN.1-adapted vaccine will be available across the EU, though availability ...

We are stronger when we are all protected against respiratory diseases,” said Dr. Tomas Aragon, public health officer for ...

We’re still asking people with COVID to jump through far too many hoops to get their hands on Pfizer Inc.’s Paxlovid.” ...